Loading clinical trials...
Loading clinical trials...
An Open-Label, Phase 2 Study to Treat Patients With Renal Allograft and Polyoma BK Viruria to Prevent Polyoma BK Viremia, Polyoma BK Nephropathy and Renal Allograft Rejection
Conditions
Interventions
Leflunomide and orotic acid
Locations
9
United States
University of Alabama, Birmingham
Birmingham, Alabama, United States
Tampa General Hospital
Tampa, Florida, United States
Rush Univeristy
Chicago, Illinois, United States
University of Illinois, Chicago
Chicago, Illinois, United States
The University of Chicago Transplant Center
Chicago, Illinois, United States
IU Health
Indianapolis, Indiana, United States
Start Date
July 1, 2012
Primary Completion Date
June 1, 2018
Completion Date
June 1, 2018
Last Updated
December 5, 2018
NCT05432778
NCT05224583
NCT05769582
NCT00002663
NCT00793598
NCT01488526
Lead Sponsor
Changzheng-Cinkate
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions